var data={"title":"Pentoxifylline: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pentoxifylline: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6752?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pentoxifylline-drug-information\" class=\"drug drug_general\">see &quot;Pentoxifylline: Drug information&quot;</a> and <a href=\"topic.htm?path=pentoxifylline-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pentoxifylline: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208251\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Pentoxifylline SR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054849\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Blood Viscosity Reducer Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054843\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=pentoxifylline-drug-information\" class=\"drug drug_general\">see &quot;Pentoxifylline: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Kawasaki disease; adjunctive:</b> Limited data available, efficacy results variable (Nash 1996); AHA recommendations do not address pentoxifylline for the treatment of Kawasaki disease (AHA [McCrindle 2017]): Infants &ge;2 months and Children: Oral: 20 mg/kg/day in 3 divided doses in combination with standard IV immunoglobulin and aspirin therapy; specific role in disease management undefined; data suggests use in patients with high serum concentrations of TNF may be appropriate (Best 2003; Furukawa 1994); the initial trial (n=22, mean age: 2 years, youngest: 6 months) reported a lower incidence of coronary artery lesions in patient receiving pentoxifylline compared to those who did not; all patients received aspirin and IV gamma globulin therapy (Furukawa 1994).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: 400 mg 3 times/day with meals; decrease to 400 mg twice daily if CNS or GI side effects occur. <b>Note:</b> Although clinical benefit may be seen within 2 to 4 weeks, treatment should be continued for at least 8 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Use with caution; monitor for enhanced therapeutic and toxic effects; <b>Note:</b> Pentoxifylline is not eliminated unchanged in the urine; however, the pharmacologically active metabolite (M-V) is; M-V may accumulate in patients with renal impairment and add to pharmacologic and toxic effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Dosage adjustments not listed by manufacturer; adjust dose based on degree of renal impairment (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;50 mL/minute: 400 mg every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 10 to 50 mL/minute: 400 mg every 12 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;10 mL/minute: 400 mg every 24 hours; <b>Note:</b> Further dosage reduction may be required; Paap (1996) suggests a further reduction to 200 mg once daily but current products (extended or controlled release; unscored) may require adaptation to 400 mg once every other day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208229\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 400 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208215\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054852\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer with food or antacids to decrease GI upset. Do not crush, break, or chew extended or controlled release tablet, swallow whole.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F554088\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store between 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054851\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of intermittent claudication on the basis of chronic occlusive arterial disease of the limbs (FDA approved in adults). <b>Note:</b> In adults, may improve function and symptoms, but not intended to replace more definitive therapy. <b>T</b>he American College of Chest Physicians (ACCP) discourages the use of pentoxifylline for the treatment of intermittent claudication refractory to exercise therapy (and smoking cessation) (Guyatt 2012). Has also been used as adjunct therapy for treatment of Kawasaki disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208304\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pentoxifylline may be confused with tamoxifen </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">TRENtal may be confused with Bentyl, TEGretol, Trandate</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208302\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylactic shock, anaphylactoid reaction, anaphylaxis, angioedema, angina pectoris, anorexia, aplastic anemia, aseptic meningitis, blurred vision, cardiac arrhythmia, chest pain, cholecystitis, conjunctivitis, decreased serum fibrinogen, depression, dyspnea, hallucination, hepatitis, hypotension, increased liver enzymes, jaundice, leukemia, leukopenia, pancytopenia, scotoma, seizure, tachycardia, thrombocytopenia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208235\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Patients previously exhibiting intolerance to pentoxifylline, xanthines (eg, caffeine, theophylline), or any component of the formulation; recent cerebral and/or retinal hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in U.S. labeling): Acute MI, severe coronary artery disease when myocardial stimulation might prove harmful, peptic ulcers (current or recent)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208219\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylaxis/anaphylactoid reactions: Discontinue at first sign of anaphylaxis or anaphylactoid reaction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment; the bioavailability of pentoxifylline and metabolite I is increased. Has not been studied in patients with severe hepatic disease. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; bioavailability of active metabolite V may be increased.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in the elderly due to the potential for cardiac, hepatic, or renal impairment. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208290\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208224\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12694&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Pentoxifylline may enhance the antiplatelet effect of Agents with Antiplatelet Properties. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: Pentoxifylline may enhance the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May increase the serum concentration of Pentoxifylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofloxacin (Systemic): May increase the serum concentration of Pentoxifylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Strong): May increase the serum concentration of Pentoxifylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparin: Pentoxifylline may enhance the anticoagulant effect of Heparin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparins (Low Molecular Weight): Pentoxifylline may enhance the anticoagulant effect of Heparins (Low Molecular Weight). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Nasal): May enhance the adverse/toxic effect of Pentoxifylline. Specifically, the risk of bleeding may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Systemic): May enhance the adverse/toxic effect of Pentoxifylline. Specifically, the risk of bleeding may be increased with this combination.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Pentoxifylline may increase the serum concentration of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Pentoxifylline may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208246\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food may decrease rate but not extent of absorption. Pentoxifylline peak serum levels may be decreased if taken with food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208226\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208238\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Information related to use in pregnant women has not been located. Pentoxifylline may be used to test sperm viability when evaluating nonfertile males (ASRM, 2012). It has also been evaluated for the treatment of infertility due to endometriosis, but use for this purpose is not currently recommended (Lu, 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208218\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Pentoxifylline increases blood flow to the affected microcirculation. Although the precise mechanism of action is not well-defined, blood viscosity is lowered, erythrocyte flexibility is increased, leukocyte deformability is increased, and neutrophil adhesion and activation are decreased. Overall, tissue oxygenation is significantly increased.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208234\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: 2 to 4 weeks with multiple doses </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Well absorbed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic to multiple metabolites; undergoes extensive first-pass effect; Pentoxifylline undergoes reduction to metabolite I (active), and oxidation to form metabolite V (active) (Ward 1987); <b>Note: </b>Plasma concentrations of M-1 and M-V are 5 and 8 times greater, respectively, than pentoxifylline </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Parent drug: 24 to 48 minutes; Metabolites: 60 to 96 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 2 to 4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (0% as unchanged, 50% to 80% as M-V metabolite, 20% as other metabolites); feces (&lt;4%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10806425\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">A 20 mg/mL oral suspension may be made using tablets. Crush ten 400 mg tablets and reduce to a fine powder. Add a small amount of purified water and mix to a uniform paste; mix while adding purified water to <b>almost</b> 200 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 200 mL. Label &quot;shake well&quot; and &quot;refrigerate&quot;. Stable 91 days.</p>\n    <div class=\"reference\">Nahata MC, Pai VB, and Hipple TF, <i>Pediatric Drug Formulations</i>, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208237\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Pentoxifylline ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (100): $114.05</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208240\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Agapurin (HU, PK, VN);</li>\n      <li>Ahapuryn (UA);</li>\n      <li>Angiopurin (HU);</li>\n      <li>Artal (FI);</li>\n      <li>Artelife (MX);</li>\n      <li>Cental (TW);</li>\n      <li>Cerator (MY, TH);</li>\n      <li>Ceretal (TW);</li>\n      <li>Chinotal (HU);</li>\n      <li>Circulaid (JO);</li>\n      <li>Clem (PY);</li>\n      <li>Dartelin (HR);</li>\n      <li>Duplat (MX);</li>\n      <li>Elorgan (ES);</li>\n      <li>Fixoten (MX);</li>\n      <li>Flexital CR (TH);</li>\n      <li>Fylin (TW);</li>\n      <li>Hemovas (ES);</li>\n      <li>Ipentol (TW, VN);</li>\n      <li>Kentadin (MX);</li>\n      <li>Nelorpin (ES);</li>\n      <li>Oxiflux (RO);</li>\n      <li>Oxopurin 400 SR (IL);</li>\n      <li>Penphylline (TW);</li>\n      <li>Pentamon (HR);</li>\n      <li>Pentilin (HR, LV);</li>\n      <li>Pentolin (BD);</li>\n      <li>Pentox (PH);</li>\n      <li>Pentox von ct (LU);</li>\n      <li>Pentoxal (PH);</li>\n      <li>Pentoxi (CH);</li>\n      <li>Pentoxifilina (CO);</li>\n      <li>Pentoxifyllin AL (HU);</li>\n      <li>Pentoxifyllin Pharmavit (HU);</li>\n      <li>Pentoxifyllin-B (HU);</li>\n      <li>Pentoxifyllin-ratiopharm (LU);</li>\n      <li>Pentoxin SR (KR);</li>\n      <li>Pentoxine (JO, QA);</li>\n      <li>Pentyllin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Perencal (KR);</li>\n      <li>Peridane (MX);</li>\n      <li>Pexal (BM, BZ, GY, SR);</li>\n      <li>Pexol (PE);</li>\n      <li>Platof (ID);</li>\n      <li>Profiben (MX);</li>\n      <li>Qiquan (CN);</li>\n      <li>Rentylin (LU);</li>\n      <li>Sufisal (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Tarontal (GR, ID, TR);</li>\n      <li>Torental (BE, FR, LU);</li>\n      <li>Trenfyl (ID);</li>\n      <li>Trenlin (HK);</li>\n      <li>Trenlin SR (SG);</li>\n      <li>Trental (AE, AR, AT, AU, BB, BD, BG, BH, BM, BO, BR, BS, BZ, CH, CL, CO, CR, CU, CY, CZ, DE, DK, DO, EC, EE, EG, FI, GB, GT, GY, HK, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KR, KW, LB, LT, LV, LY, MT, MX, MY, NI, NL, NO, NZ, OM, PA, PE, PH, PK, PL, PR, PT, PY, QA, RU, SA, SE, SG, SI, SK, SR, SV, SY, TH, TR, TT, TW, UA, UY, VE, YE);</li>\n      <li>Trental SR (EG);</li>\n      <li>Trental-400 (LK);</li>\n      <li>Vantoxyl (MX);</li>\n      <li>Vasolax (BD);</li>\n      <li>Vasonit (AT, RO);</li>\n      <li>Vasonit Retard (LV);</li>\n      <li>Vasopentox (PE);</li>\n      <li>Xipen (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians, 2007, 117.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff SC, Quinn FJ, Carpenter LS, et al, &ldquo;Effects of Pentoxifylline on Sputum Neutrophil Elastase and Pulmonary Function in Patients With Cystic Fibrosis: Preliminary Observations,&rdquo; <i>J Pediatr</i>, 1994, 125(6 Pt 1):992-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/7996376/pubmed\" target=\"_blank\" id=\"7996376\">7996376</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berman W Jr, Berman N, Pathak D, et al, &ldquo;Effects of Pentoxifylline (Trental&reg;) on Blood Flow, Viscosity, and Oxygen Transport in Young Adults With Inoperable Cyanotic Congenital Heart Disease,&rdquo; <i>Pediatr Cardiol</i>, 1994, 15(2):66-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/7997416/pubmed\" target=\"_blank\" id=\"7997416\">7997416</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Best BM, Burns JC, DeVincenzo J, et al. Pharmacokinetic and tolerability assessment of a pediatric oral formulation of pentoxifylline in kawasaki disease. <i>Curr Ther Res Clin Exp</i>. 2003;64(2):96-115.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/24944359/pubmed\" target=\"_blank\" id=\"24944359\">24944359</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guyatt GH, Akl EA, Crowther M, et al. Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest.</i> 2012;141(2 Suppl):7-47.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Furukawa S, Matsubara T, Umezawa Y, et al, &ldquo;Pentoxifylline and Intravenous Gamma Globulin Combination Therapy for Acute Kawasaki Disease,&rdquo; <i>Eur J Pediatr</i>, 1994, 153(9):663-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/7957426/pubmed\" target=\"_blank\" id=\"7957426\">7957426</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lauterbach R, &ldquo;Pentoxifylline Treatment of Persistent Pulmonary Hypertension of Newborn,&rdquo; <i>Eur J Pediatr</i>, 1993, 152(5):460. (I.V. use)<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/8319723/pubmed\" target=\"_blank\" id=\"8319723\">8319723</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lauterbach R, Pawlik D, Tomaszczyk B, et al, &ldquo;Pentoxifylline Treatment of Sepsis of Premature Infants; Preliminary Clinical Observations,&rdquo; <i>Eur J Pediatr</i>, 1994, 153(9):672-4. (I.V. use)<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/ 7957428 /pubmed\" target=\"_blank\" id=\" 7957428 \"> 7957428 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lu D, Song H, Li Y, et al, &quot;Pentoxifylline for Endometriosis,&quot; <i>Cochrane Database Syst Rev</i>, 2012, 1:CD007677.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/22258970/pubmed\" target=\"_blank\" id=\"22258970\">22258970</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacDonald MJ, Shahidi NT, Allen DB, et al, &ldquo;Pentoxifylline in the Treatment of Children With New-Onset Type I Diabetes Mellitus,&rdquo; <i>JAMA</i>, 1994, 271(1):27-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/8258882/pubmed\" target=\"_blank\" id=\"8258882\">8258882</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. <i>Circulation</i>. 2017;135(17):e927-e999.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/28356445/pubmed\" target=\"_blank\" id=\"28356445\">28356445</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nash MC, Wade AM. No evidence for use of pentoxifylline in acute Kawasaki disease. <i>Eur J Pediatr</i>. 1996;155(3):258.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/8929744/pubmed\" target=\"_blank\" id=\"8929744\">8929744</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Paap CM, Simpson KS, Horton MW, et al, &quot;Multiple-Dose Pharmacokinetics of Pentoxifylline and Its Metabolites During Renal Insufficiency,&quot; <i>Ann Pharmacother</i>, 1996, 30(7-8):724-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/8826548/pubmed\" target=\"_blank\" id=\"8826548\">8826548</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pentoxifylline [prescribing information]. Morgantown, WV: Mylan; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Practice Committee of American Society for Reproductive Medicine, &quot;Diagnostic Evaluation of the Infertile Male: A Committee Opinion,&quot; <i>Fertil Steril</i>, 2012, 98(2):294-301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/22698639/pubmed\" target=\"_blank\" id=\"22698639\">22698639</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trental (pentoxifylline) [prescribing information]. Parsippany, NJ: Validus; January 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ward A and Clissold SP. Pentoxifylline: A Review of Its Pharmacodynamic and Pharmacokinetic Properties and Its Therapeutic Efficacy. <i>Drugs.</i> 1987;34(1):50-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/3308412/pubmed\" target=\"_blank\" id=\"3308412\">3308412</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Witter FR and Smith RV, &quot;The Excretion of Pentoxifylline and Its Metabolites Into Human Breast Milk,&quot; <i>Am J Obstet Gynecol</i>, 1985, 151(8):1094-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/3985069/pubmed\" target=\"_blank\" id=\"3985069\">3985069</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12694 Version 120.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F208251\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1054849\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1054843\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F208229\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F208215\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1054852\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F554088\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1054851\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F208304\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F208302\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F208235\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F208219\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F208290\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F208224\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F208246\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F208226\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F208238\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F208218\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F208234\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F10806425\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F208237\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F208240\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12694|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pentoxifylline-drug-information\" class=\"drug drug_general\">Pentoxifylline: Drug information</a></li><li><a href=\"topic.htm?path=pentoxifylline-patient-drug-information\" class=\"drug drug_patient\">Pentoxifylline: Patient drug information</a></li></ul></div></div>","javascript":null}